BioSpace News Archive

Robotic surgery can be more profitable than laparoscopy, according to a new peer review journal study co-authored by CAVA Robotics CEO Josh Feldstein and Dr. Ali Ghomi, Chairman, Department of Obstetrics and Gynecology, Sisters of Charity Hospital, Buffalo, NY.

ObsEva SA announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021.

As part of Sanofi’s endeavor to accelerate the application of messenger RNA to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio, a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion.

According to the report, the global targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and is projected to expand at a moderate CAGR during the forecast period.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact. MR analysis, the Americas hematology diagnostics market is forecast to reach a valuation of US$ 451 Mn by 2031 end.

According to the report, the global metformin hydrochloride API market was valued at ~US$ 300 Mn in 2020 and is projected to expand at a CAGR of ~5% from 2021 to 2031.

According to the report, the global lyophilized injectable market was valued over US$ 2.8 Bn in 2020 and is projected to expand at a CAGR of ~5% from 2021 to 2031.

The gadgets utilized in the medical care settings for the reprocessing techniques of the endoscopes are called endoscope reprocessing gadgets.

Aurora Spine Corporation, a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced it had received U.S. Food and Drug Administration 510 Clearance for its DEXA-C, a new line of cervical cages for anterior cervical discectomy with fusion procedures.

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today that medac, Medexus’ licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for treosulfan.